Abstract. Meningiomas are generally slow-growing benign tumours; however, recurrent cases are associated with a poor prognosis. As these tumours are commonly grouped according to their grade of malignancy, it is difficult to define tumourspecific alterations involved in their genesis and evolution. Genetic comparative studies of primary and recurrent tumours are important for the identification of the chromosomal, genetic and proliferative alterations that are possibly involved in the process of malignancy in this class of tumour. We performed interphase fluorescence in situ hybridization using region-specific probes comprising the genes MYCN, ERBB4, CDH1, ABR, ERBB2 and NF2 as well as AgNOR staining in a sample of primary and relapsed chordoid meningiomas. Significant differences were found in these samples regarding the genes NF2, MYCN, ABR and ERBB2. Cell proliferation levels also showed a significant difference. The results suggest the involvement of the MYCN gene in the evolution of meningiomas.
Introduction
Meningiomas are the most frequently occurring non-glial brain primary tumours, benign in 90% of cases and presenting slow growth (1, 2) . It is well-known that total or partial monosomy 22 is the most consistent chromosomal aberration found in meningiomas (2) (3) (4) (5) . Other chromosomal alterations include deletions of 1p, 3p, 6q, 9p, 10q and 14q (4, (6) (7) (8) (9) (10) (11) .
Mutations in the tumour suppressor gene NF2 were detected in more than 60% of sporadic meningiomas (2, 5, (12) (13) (14) . Other uncommon molecular alterations include the deletion of the genes PTEN (10q23) and CDKN2C (1p32), and amplification of the gene PS6K (17q23) (6, 15, 16) .
Chordoid meningiomas (WHO grade II) contain regions histopathologically similar to chordomas, intercalated with meningioma-typical regions (17) . Relatively little genetic information is available regarding this specific type of tumour, although reverse FISH studies in three chordoid meningiomas revealed a der(1)t(1;3)(p12-13;q11) in all samples and monosomy of chromosomes 6, 10, 11, 18 and 22 in one of the cases (18) . Factors apparently associated with meningioma recurrence include malignant histology, high proliferation levels of tumour cells, unfavourable tumour localization, incomplete surgical dissection and monosomy 14. However, recurrence is still observed in histopathologically benign tumours and in tumours without monosomy 14 (19, 20) , as well as after complete resection (21) . Usually, recurrence is associated with a poor prognosis (22) .
Cell proliferation studies using AgNOR staining have been used to establish a positive correlation between the increased average number of nuclear organizer regions (NORs) in nuclei and aggressivity and/or poor prognosis. Some examples of the application of this technique have been published concerning oral cancer (23) , uterine lesions (24) and nervous system tumours (25) (26) (27) (28) .
The aim of this study was to investigate cell proliferation levels using AgNOR staining, as well as the occurrence of amplification/deletion of chromosome regions, including the genes MYCN and ERBB4 (chromosome 2), CDH1 (chromosome 16), ABR and ERBB2 (chromosome 17) and NF2 (chromosome 22), by applying interphase FISH in a case of chordoid meningioma and its relapsed tumour.
Materials and methods
Case report. This analysis was conducted with the approval of the CEP-CCS/UFPA Committee (029/06). A 36-year-old woman was repeatedly surgically treated for the presence of a meningioma at the Hospital Ophir Loyola (Belém, PA, Brazil). Both primary and recurrent tumours were resected subtotally. The second surgery occurred three months after the first. The patient was not treated by chemotherapy/radiotherapy before or after any of the surgeries. Eighteen months after the second surgery, the patient is alive and without traces of re-incident tumours. Histopathologic analysis confirmed chordoid meningioma in both tumours according to the WHO classification (17, 29) . A non-recurrent meningothelial meningioma sample and a lymphocyte culture from a healthy individual were used as controls (30) . Consent for publication in print was obtained from the patient.
Cytological preparations. Interphase nuclei were obtained from tissue samples according to Ford and Hamerton (31) , with modifications. Chromosome and interphase preparation from a healthy individual were obtained from standard lymphocyte cultures (RPMI-1640 medium, 72-h incubation, 0.2 mg/ml colcemid for 60 min).
Interphase fluorescence in situ hybridization. Locus regionspecific FISH probes were chosen after careful review in previously published studies. They included genes that are involved in the genesis and development of various types of nervous system tumours (Table I) (17, (32) (33) (34) (35) (36) . For iFISH analysis, the locus-specific probes were obtained from BACs for genes MYCN (RP11-463P22), ERBB4 (RP11-44A23), CDH1 (RP11-401A12), ABR (RP11-216P06), ERBB2 (RP11-61O22) and NF2 (RP11-155B12). In addition, a probe from BAC in the 22q11.23 (RP11-464B20) region was used with the NF2 probe as a control for chromosomal alterations (37) . All the probes were obtained from BAC PAC chori or the Sanger Centre and labelled with Texas Red or Fluorescein. Dual and single colour FISH and signal detection were carried out as described previously (38) . Briefly, slides were dehydrated and incubated for 2 h at 65˚C. Standard techniques were used for denaturation, hybridization, stringency washes and detection. The material was counterstained with DAPI. Hybridization results were examined and analyzed using a Zeiss Axioplan2 fluorescent microscope and Smartcapture 4.1 software. For analysis, we used the criteria found in Carlson et al (39) : nuclei of 2-3 different areas were examined in each experiment, totalling 80-120 nuclei. Regions with a high background level or without at least one signal of each probe were not included. Two distinct region-specific probes of the same chromosome (2, 17 and 22) were analyzed together and independently in order to offer additional information regarding these chromosomes (37) .
AgNOR staining. Staining of NORs was performed according to Howell and Black (40) . For each sample, 200 intact nuclei, chosen by chance, were analyzed using a Zeiss Axioplan microscope.
Statistical analysis. The levels of significance of the results of AgNOR and iFISH analysis in the different samples were verified by the non-parametric Mann-Whitney U test. Levels were considered significant at p<0.05. Table II shows the results of the analysis of two distinct region-specific probes of the same chromosome (2, 17 and 22) . A simultaneous increase in the signal number of the two probes on the same chromosome was taken to indicate aneuploidy, while alterations in the number of signals of only one probe were considered deletions or amplifications of the gene without the occurrence of aneuploidy of its respective chromosome.
Results
In peripheral blood lymphocytes, a very low frequency of altered of signals (0-2.5%) was found for all the probes. In general, tumour tissues revealed high levels of alterations for chromosome 22, reaching 62.9% in the meningothelial meningioma, 78.3% in the primary chordoid meningioma (PCM) and 98.2% in the recurrent chordoid meningioma (RCM) ( Table II) .
Alterations in chromosome 2 (genes MYCN and ERBB4) were less evident in all the samples; however, amplification of the gene MYCN, including or not the deletion of gene ERBB4, was observed in 32.2% of nuclei in meningothelial meningioma, 29.7% of those in PCM and 35.6% of those in RCM. The gene ERBB4 was altered in fewer nuclei, and its deletion was more frequent than its amplification. The PCM and RCM did not exhibit significant differences (p≥0.05) for this gene.
The genes ABR and ERBB2 (chromosome 17), when analyzed alone, showed normal results in >50% of the nuclei in chordoid meningiomas; however, monosomy values for these genes in meningothelial meningioma reached 40.8 and 53.3%, respectively.
The gene CDH1 (chromosome 16) was normal in ~40% of the meningioma samples. In recurrent chordoid meningioma, this gene was amplified in 45.8% of nuclei, while in the meningothelial meningioma it was deleted in 33.6%.
NOR analysis revealed the number of signals rising from 1.88% in the lymphocyte cultured material to 3.31% in the RCM (Fig. 1A and B) , with significant differences among the samples (p<0.05) (Table III) .
Discussion
The analysis of alterations in gene dosage and expression in cancer can yield important insights into the mechanism of Table I . Characterization of the selected probes and types of tumours in which the genes showed some degree of alteration. Table II . Number of signals (%) for each probe per nucleus. Table II . Continued.
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Meningioma genesis is usually associated with alterations in chromosomes 1, 3, 6, 9, 10 and 22, while anomalies in chromosome 14 reflects poor prognosis and a predisposition to recurrence (2-4,7,9-11,21 ). Although these alterations have been identified, none can explain all cases of meningioma genesis or recurrence. This fact highlights the need for more studies on specific meningioma subtypes, as well as for the analysis of other genes, in particular those for which little information is available.
The most frequently altered gene among the meningiomas analyzed was NF2, which was amplified in more than 80% of nuclei in the RCM. This finding is in disagreement with previous studies, which argued that partial or total monosomy 22 is the most frequent alteration in meningiomas (2-5).
Our results indicate that distinct types of meningiomas may correspond to genetically heterogeneous groups. Tumor suppressor genes (TSGs) such as NF2 are negative regulators of cellular growth, and the inactivation of both alleles can confer advantage to the cell and promote neoplastic growth (4). Hence, amplifications of TSGs are not associated with tumorigenesis, unless a constitutional aberration, such as small deletions in NF2, could be involved in the inactivation of this gene prior to the gain of extra copies of chromosome 22.
Two reports have been published to date concerning the cytogenetic analysis of the MYCN gene in meningothelial tumours. One used a cell line and did not observe significant alterations (41) , and the second employed Southern blotting to analyze a paediatric meningioma (42) . However, in the present study, alterations involving this gene, in particular amplifications, were observed in all the meningioma samples: meningothelial meningioma (35.7%), PCM (48.5%) and RCM (59.4%). This fact could be indicative of a significant role for MYCN in the genesis and/or progression of some types of meningiomas.
The gene ERBB4, also found in chromosome 2, was altered to a much lesser degree in the neoplastic samples. When altered, this gene was in most instances deleted. Due to this discordance in the number of signals of the genes MYCN and ERBB4, we can assume that the amplification of MYCN occurs without the involvment of the whole chromosome. In the literature, partial or total deletions of chromosome 2 were only related in one sample of fibroblastic meningioma (43) and in two samples of grade III meningioma (44) .
The ABR gene is functionally active in chromosome 17p (45) . This gene was found deleted in seven of eight samples of medulloblastoma, which suggests the existence of other tumour supressor genes in this chromosome, apart from TP53 (32) . In the present study, in meningothelial meningioma, the ABR gene was normal or in monosomy in 45 and 40.8% of nuclei, respectively. A similar high incidence of monosomy was observed for ERBB2, also found in chromosome 17. This fact suggests that chromosome 17 is in total or partial monosomy in approximately 40% of nuclei in this sample. It could be speculated that this partial or total monosomy observed in meningothelial meningioma is a secondary consequence of monoclonal carcinogenic expansion, or that this sample is actually polyclonal, which, in fact, has been observed in a few samples of meningioma (46) . More samples must be analyzed if the role of ABR in meningiomas is to be determined.
In chordoid meningiomas, the CDH1 gene was normal in nearly 40% of nuclei, and the frequency of amplification was higher than deletions in both samples. Although there are no previous cytogenetic reports involving this gene in this type of tumour, the results support the notion that the expression of this gene in recurrent tumours is identical to the expression observed in the primary tumour when there is no malign progression (47) .
AgNOR analysis revealed a significant difference between meningothelial and chordoid meningiomas. This fact corroborates the proposal of Schiffer et al (48) that the high number of recurrences in atypical and anaplastic tumours depends on their high initial capacity for cell proliferation. The gradual increase in AgNOR index according to the increase in tumour grade observed in our results could reflect the great necessity for genetic transcription in these tumours, compatible with the level of cell propagation.
In conclusion, all the genes analyzed in this report showed some level of alteration in primary and recurrent chordoid meningiomas, with significant differences among the samples of the genes NF2, MYCN, ABR and ERBB2. Levels of cell proliferation among these neoplasias also showed significant differences. The results indicate that, although the differences are statistically significant, cell populations have similar genetic profiles. This corroborates Leuraud et al (30) , who proposed a monoclonal origin for both initial and recurrent tumours.
Finally, our results reveal the need for a more intense analysis of the behavior of MYCN in some types of meningioma, as well as the total or partial monosomy of chromosome 17 as an alteration that occurs in a group of meningothelial meningiomas. The high incidence of amplification of NF2 observed, which conflicts with previous data, may indicate that meningiomas are heterogeneous and should be analyzed in subgroups.
